Informing the pharmaceutical drug development and commercialization industry.
Cary, N.C. – February 25, 2014 – Industry Standard Research (ISR) has announced the availability of a new report titled “Forest Labs Clinical Development Profile.” This report provides a thorough analysis of Forest Laboratories’ R&D pipeline, clinical trial activity, patents, FDA submissions, and includes profiles of Forest’s key products.
“In Forest’s January 2014 financial conference call they noted that ‘Research and Development spending for the current quarter was approximately $220 million as compared to $325 million reported in the third quarter last year, a reported decrease of 33%,’” explained Andrew Schafer, President of ISR.
“We certainly did not see Forest’s recent acquisition of Aptalis coming or the more recent offer by Actavis to buy Forest Labs for $25 Billion. However, we did realize that Forest was a company in play,” Schafer continued.
ISR’s report provides pharmaceutical companies and service providers with a look into Forest’s individual drug sales and company financial condition over the past four years, the number, length, and patient enrollment of clinical trials segmented by phase and trial type, and Forest’s R&D pipeline with mechanism of action identified. This data will help service providers better understand Forest’s clinical pipeline while giving sponsors an idea of how these competing compounds may affect the launch of similar products.
For more information on ISR’s “Forest Labs Clinical Development Profile” report, please visit ISR’s report page at https://isrreports.com/product/forest-labs-clinical-development-profile/.
About Industry Standard Research
Industry Standard Research is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience, ISR delivers an unmatched level of domain expertise. For more information about our off-the-shelf intelligence and custom research offerings, please visit the company’s Web site at www.ISRreports.com, email info@ISRreports.com, or follow us on Twitter @ISRreports.
